Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

Biologics Resources

Find information about our functional bioassays for biologic drug discovery. View scientific presentations and posters with the latest technology and data to help with your research needs.

Join us at these events to learn more about our latest Biologics products and applications:

BEBPA Europe, Sept 20–23
Macrophage-Directed Cell Therapies, Sept 28–30
PEGS Europe, Nov 2–4
SITC, Nov 10–14
AET, Dec 12–16

Scientific Presentations

jey-cheng-125x125

SARS-CoV-2 Bioassays

Presented by Jey Cheng, Sr Research Scientist, Promega Corporation

This presentation introduces bioassays developed to address the two major mechanisms of action for SARS-CoV-2 antibodies. You will learn about:

  • The SARS-CoV-2 HiBiT-PsVLP Assay for neutralization activity
  • ADCC/ADCP Reporter Bioassays for antibody Fc effector function
Download PDF

jey-cheng-125x125

Bioluminescent Bioassays: From Reporter Cell Lines to Primary Cells

Presented by Jey Cheng, Sr Research Scientist, Promega Corporation

This presentation introduces our portfolio expansion into primary cell-based assays for immunotherapeutic drug development. You will learn about:

  • Using HiBiT-based target cells for ADCC and TDCC assays
  • NanoBiT immunoassays for measuring cytokine release 
Download PDF

4854-gilden-julia-125x125

Novel Bioluminescent Bioassays for the Discovery and Development of T Cell Redirecting Cancer Therapies

Presented by Julia Gilden, Sr Research Scientist, Promega Corporation

This presentation will discuss new bioluminescent tools to expedite the development of T cell-redirecting cancer therapies. You will learn about:

  • NanoBiT-based assay platforms that can quantitatively measure the potency of CD3 bispecific antibodies or BiTEs to induce T cell-dependent target cell killing and cytokine production.
  • TCRαβ-null reporter cell lines that can be used to screen transgenic TCRs against specific tumor antigen targets. 
Download PDF

See lists of peer-reviewed publications that used our reporter bioassays for viral vaccine research and immunotherapy drug development assays including mAb therapeutics, bispecific antibodies, oncolytic virus therapy, cancer vaccines, gene therapy and biosimilars.

Bioassays for BiologicsViral Vaccine Development

Scientific Posters

jey-cheng-125x125

Developing a Bioluminescent PBMC ADCC Assay for the Discovery and Characterization of Therapeutic Antibodies
Presented by Jey Cheng, Sr. Research Scientist

Download PDF

jamison-grailer-125 Cell-Based Reporter Bioassays for Development of Fc-Functional and Fc-Silent SIRPa/CD47 Checkpoint Inhibitors

Presented by Jamison Grailer, Sr Research Scientist

Download PDF

jamison-grailer-125

Quantitative Cell-Based Bioassays to Advance Immunotherapy Programs Targeting Immune Checkpoint Receptors
Presented by Jamison Grailer, Sr Research Scientist

Download PDF

jeff-nelson-125x125 A No-Wash, Rapid FcRn Binding Immunoassay to Guide the Design and Development of Antibody Therapeutics

Presented by Jeff Nelson, Product Manager

Download PDF

New Products

PBMC ADCC Bioassay

Perform your ADCC method bridging studies with the new PBMC ADCC Bioassay, featuring pre-qualified PBMCs. The assay offers improved consistency and robustness for measuring ADCC. Each assay includes ADCC-qualified PBMC effector cells and a choice of popular target cells expressing a HiBiT fusion protein. The simple, add-mix-read format uses bioluminescent detection for maximum sensitivity.

Learn More
In this video interview, Senior Research Scientist Jey Cheng answers common questions about the PBMC ADCC Bioassay.

Lumit™ Immunoassays

Replace conventional immunoassays, such as Western blots and ELISAs, with new Lumit™ Immunoassays. These assays offer direct luminescence measurement in cell culture, broad dynamic range, and can be completed in as little as 30 minutes.

Lumit™ Immunoassays are available for a range of applications, including protein phosphorylation and pathway analysis, FcRn binding, cytokine detection, metabolite research, and more. You can also build your own Lumit™ immunoassays with our labeling and detection kits.

Learn More

Lumit immunoassay principle

General principle of a Lumit™ Immunoassay. Antibodies are chemically labeled with the small and large subunits of NanoLuc® Luciferase, known as SmBiT and LgBiT, respectively. In the presence of an analyte, the two antibodies come into close proximity, allowing SmBiT and LgBiT to form an active enzyme and generate a bright luminescence signal.